While Motor Neurone Disease (MND) is currently a life-shortening condition without a known cure, the focus of modern medical care in the United Kingdom is on slowing the progression of the disease and maximising quality of life. Treatment is managed through a multidisciplinary approach, involving a team of specialists who coordinate care as symptoms evolve. This includes everything from medication and nutritional support to advanced respiratory care and assistive technology.
In the UK, the National Health Service (NHS) provides access to licensed medications and essential supportive therapies. Recent years have also seen significant strides in research, with new drug candidates and clinical trials offering pathways toward more personalized and effective treatments. This article outlines the current medical landscape and the various options available to those living with MND.
What We Will Discuss In This Article
- Disease-modifying medications licensed in the UK
- New targeted therapies including Tofersen for genetic subtypes
- Management of physical symptoms such as cramps and spasticity
- Support for breathing and nutritional needs
- Current clinical trials and the future of MND research
- Emergency guidance for acute respiratory or neurological changes
Disease-Modifying Medications
The primary goal of medication in MND is to protect motor neurones and extend the period of functional independence.
Riluzole
Riluzole is the only drug currently licensed in the UK for all types of MND and is widely available on the NHS. It works by reducing the levels of glutamate, a chemical messenger that can damage motor neurones when it accumulates to toxic levels. It is available in both tablet and liquid form. While it does not reverse the disease, it is proven to extend life expectancy and can help delay the need for more intensive supportive measures.
Tofersen (Qalsody)
Tofersen was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2025. This is a pioneering genetic therapy specifically for people with MND caused by mutations in the SOD1 gene. It works by stopping the body from producing the toxic version of the SOD1 protein. While it undergoes final assessments for routine NHS funding, many patients access it through early access schemes at specialist centres.
Symptom Management and Physical Care
A significant portion of MND treatment is dedicated to addressing the daily physical symptoms that affect comfort and mobility.
- Muscle Cramps and Stiffness: Medications such as quinine are often prescribed for cramps, while baclofen, tizanidine, or gabapentin are used to treat spasticity (muscle stiffness) and promote relaxation.
- Excessive Saliva: When swallowing becomes difficult, saliva can pool. This is managed using anticholinergic medications like hyoscine patches or glycopyrrolate.
- Emotional Lability: Some people experience uncontrollable laughing or crying (pseudobulbar affect), which can be stabilized with specific medications.
Supportive Interventions for Breathing and Nutrition
As MND affects the muscles responsible for breathing and swallowing, timely intervention in these areas is crucial.
Respiratory Support
Non-invasive ventilation (NIV) is the standard treatment for breathing difficulties. It involves wearing a mask, usually at night, connected to a machine that supports the lungs. This significantly reduces fatigue and improves sleep quality.
Nutritional Support
If swallowing becomes unsafe or if weight loss occurs, a gastrostomy tube may be recommended. This is a small tube placed directly into the stomach (PEG or RIG) through which liquid nutrition, hydration, and medication can be delivered.
The Research Pipeline and Clinical Trials
The UK is a global leader in MND research, with several large-scale trials investigating new ways to treat the condition.
| Trial / Drug | Focus | Status (UK) |
| MND-SMART | Testing repurposed drugs simultaneously | Ongoing recruitment |
| EXPERTS-ALS | Rapidly prioritizing drugs using biomarkers | Recently launched |
| M102 | Neuroprotective candidate from Sheffield | Moving to human trials |
Emergency Guidance
While MND is a progressive condition, certain situations require immediate medical intervention. Seek emergency care immediately if you experience:
- Sudden and severe difficulty breathing or a feeling of gasping for air
- An acute episode of choking on food or liquid that cannot be cleared
- A total and sudden loss of muscle strength resulting in a fall or injury
- Rapid confusion, disorientation, or a sudden change in mental alertness
In these situations, call 999 or attend the nearest Accident and Emergency department immediately.
To Summarise
Treatment for Motor Neurone Disease focuses on a dual approach of slowing the disease with medication and managing symptoms through multidisciplinary care. While Riluzole remains the cornerstone for most, the arrival of gene-targeted therapies has opened new doors for personalised medicine. Supportive care, including NIV and gastrostomy, plays a vital role in maintaining quality of life. In the UK, the integration of clinical care with cutting-edge research remains the best defence against MND.
Is Riluzole available for all types of MND?
Yes, Riluzole is licensed for use in the UK for all forms of Motor Neurone Disease.
What is the multidisciplinary team approach?
It is a group of various specialists including neurologists, nurses, physiotherapists, and dietitians who work together to provide coordinated care.
Can I still exercise while receiving treatment?
Gentle, supervised exercise is often encouraged to maintain flexibility, provided it does not lead to extreme exhaustion.
Does NIV treat the disease itself?
NIV does not stop the disease, but it supports the lungs, reduces carbon dioxide buildup, and significantly improves survival and quality of life.
Authority Snapshot
This article was reviewed by Dr. Rebecca Fernandez, a UK-trained physician with an MBBS and extensive experience in internal medicine, general surgery, and intensive care. Dr. Fernandez has managed critically ill patients and stabilized acute trauma cases, providing her with a deep understanding of the respiratory and neurological emergencies associated with MND. Her background in psychiatry ensures a holistic approach to patient well-being, bridging the gap between physical treatment and mental health support.
